Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
ESPOO, Finland - Herantis Pharma Plc, a clinical-stage biotech company with a market capitalization of $55 million, announced Thursday that it has completed the final patient visit in its Phase 1b clinical trial evaluating HER-096 in Parkinson’s disease patients. According to InvestingPro data, the company’s stock has shown strong momentum, gaining over 30% in the past six months.
The trial’s final cohort consisted of patients receiving 300 mg doses of HER-096 or placebo administered subcutaneously twice weekly over a four-week period. The primary objective is to assess safety, tolerability and pharmacokinetics of repeated doses, while also evaluating selected biomarkers and monitoring symptoms.
Topline results from the Phase 1b trial are expected within six to nine weeks, with the full dataset including biomarker data anticipated before year-end, according to the company’s press release statement.
"We are pleased to have completed all patient dosing and follow-up visits in our Phase 1b study of HER-096," said Antti Vuolanto, CEO of Herantis Pharma.
The Phase 1b study consists of two parts. Part 1 involved eight healthy volunteers receiving a single 300 mg dose. Part 2 is a randomized, double-blind, placebo-controlled trial with Parkinson’s patients in two cohorts - the first receiving 200 mg doses and the second receiving 300 mg doses.
HER-096 is a small peptide molecule designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), targeting key drivers of neurodegeneration in Parkinson’s disease. The company is developing it as a potential first disease-modifying treatment for the condition, which affects over 10 million people worldwide.
The trial is being conducted in Finland and is funded by The Michael J. Fox Foundation for Parkinson’s Research and Parkinson’s UK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.